Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to dateMENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic data from as many as 7,800 participants. The ef ...

Core Viewpoint - Pacific Biosciences of California, Inc. (PacBio) is experiencing growth driven by product development and strong first-quarter results, despite concerns over long purchasing cycles [1][11]. Company Performance - PacBio's shares have decreased by 43.8% year-to-date, compared to a 9.2% decline in the industry, while the S&P 500 Composite has increased by 0.8% [1]. - The company has a market capitalization of $315.1 million and projects a 19.3% growth for 2025, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, averaging a surprise of 13.2% [2][12]. Product and Technology - PacBio's proprietary HiFi long-read sequencing technology, based on Single-Molecule Real-Time (SMRT) technology, enhances its market leadership by enabling high-accuracy detection of complex genomic structures [4]. - The global SMRT market is valued at $2.74 billion in 2023 and is expected to grow to $4.14 billion by 2031, with a CAGR of 5.3% [5]. - The introduction of the Onso system in 2022 and the Vega benchtop platform has expanded PacBio's offerings, allowing it to serve diverse research and clinical applications while reducing costs [5][8]. Financial Results - PacBio reported better-than-expected first-quarter results, with both earnings and revenues exceeding the Zacks Consensus Estimate, alongside a robust increase in service revenues [9]. - The company aims to achieve $45 to $50 million in annual cost savings through restructuring by the end of 2025 [6][10]. Market Challenges - PacBio faces longer purchasing cycles for its high-cost Revio sequencing system due to funding uncertainties and tighter capital budgets, particularly affecting academic and government institutions in the U.S. [11]. - Macroeconomic pressures in the Asia-Pacific region are also contributing to slower procurement timelines, which may impact near-term revenue growth [11].